Platelet-to-lymphocyte and neutrophil-to-lymphocyte ratios predict tumor size and survival in HCC patients: Retrospective study.
CT, computerized axial tomography
HCC
HCC, hepatocellular carcinoma
MTD, maximum tumor diameter
NLR
NLR, neutrophil lymphocyte ratio
PLR
PLR, platelet lymphocyte ratio
Survival
Journal
Annals of medicine and surgery (2012)
ISSN: 2049-0801
Titre abrégé: Ann Med Surg (Lond)
Pays: England
ID NLM: 101616869
Informations de publication
Date de publication:
Oct 2020
Oct 2020
Historique:
received:
17
07
2020
revised:
25
08
2020
accepted:
25
08
2020
entrez:
30
9
2020
pubmed:
1
10
2020
medline:
1
10
2020
Statut:
epublish
Résumé
Inflammation is a recognized concomitant of hepatocellular carcinoma (HCC) and its indices are prognostically useful. To evaluate two commonly used inflammatory indices, neutrophil-to-lymphocyte ratio (NLR) and the platelet-to-lymphocyte ratio (PLR), to examine their relationship to maximum tumor diameter (MTD) and to survival. A database of 1024 prospectively-accrued HCC patients was examined, who had full baseline tumor parameter data, including CT scan information on HCC size and whose survival was known. Analyses of NLR and PLR were correlated to MDT and to survival. NLR and PLR cutoffs were calculated from receiver operator characteristic curves. Every MTD pair had significantly different PLR values, for MTD groups of groups <2/≥2, <3/≥3, <4/≥4, <5/≥5 cm. However there were few significant differences in NLR values. Logistic regression models of different MTD groups likewise showed significance for PLR. Patients with both low NLR and low PLR had the longest overall survival compared to all the other 3 combinations of NLR and PLR. In a Cox regression analysis, univariate models on NLR (≤3.02/>3.02) and PLR (≤6.82/>6.82) groups, showed significance for PLR, p = 0.034 and approaching significance for NLR, p = 0.057. MTD pairs down to <2/≥2 cm showed significance for PLR, survival showed significance for PLR and almost for NLR.
Sections du résumé
BACKGROUND
BACKGROUND
Inflammation is a recognized concomitant of hepatocellular carcinoma (HCC) and its indices are prognostically useful.
AIMS
OBJECTIVE
To evaluate two commonly used inflammatory indices, neutrophil-to-lymphocyte ratio (NLR) and the platelet-to-lymphocyte ratio (PLR), to examine their relationship to maximum tumor diameter (MTD) and to survival.
METHODS
METHODS
A database of 1024 prospectively-accrued HCC patients was examined, who had full baseline tumor parameter data, including CT scan information on HCC size and whose survival was known. Analyses of NLR and PLR were correlated to MDT and to survival. NLR and PLR cutoffs were calculated from receiver operator characteristic curves.
RESULTS
RESULTS
Every MTD pair had significantly different PLR values, for MTD groups of groups <2/≥2, <3/≥3, <4/≥4, <5/≥5 cm. However there were few significant differences in NLR values. Logistic regression models of different MTD groups likewise showed significance for PLR. Patients with both low NLR and low PLR had the longest overall survival compared to all the other 3 combinations of NLR and PLR. In a Cox regression analysis, univariate models on NLR (≤3.02/>3.02) and PLR (≤6.82/>6.82) groups, showed significance for PLR, p = 0.034 and approaching significance for NLR, p = 0.057.
CONCLUSIONS
CONCLUSIONS
MTD pairs down to <2/≥2 cm showed significance for PLR, survival showed significance for PLR and almost for NLR.
Identifiants
pubmed: 32994979
doi: 10.1016/j.amsu.2020.08.042
pii: S2049-0801(20)30290-9
pmc: PMC7501491
doi:
Types de publication
Journal Article
Langues
eng
Pagination
167-171Subventions
Organisme : NCI NIH HHS
ID : R01 CA082723
Pays : United States
Informations de copyright
© 2020 The Authors.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest. All authors have read and agree with this paper.
Références
Cancers (Basel). 2019 Jul 20;11(7):
pubmed: 31330817
J Transl Sci. 2019 Jun;5(3):
pubmed: 30662766
Hepatol Res. 2020 Jan;50(1):101-109
pubmed: 31692173
Br J Cancer. 2012 Apr 10;106(8):1439-45
pubmed: 22433965
Cancers (Basel). 2020 May 21;12(5):
pubmed: 32455607
Oncotarget. 2017 Apr 4;8(14):22854-22862
pubmed: 28206965
Hepatogastroenterology. 2013 Sep;60(126):1433-7
pubmed: 23933936
Biosci Rep. 2018 Nov 13;38(6):
pubmed: 30254101
Lancet. 2001 Feb 17;357(9255):539-45
pubmed: 11229684
Hepatology. 2014 Sep;60(3):858-71
pubmed: 24443059
Gastroenterology. 2013 Mar;144(3):512-27
pubmed: 23313965
Cancer. 2005 May 1;103(9):1856-64
pubmed: 15779015
Ann Transl Med. 2020 Apr;8(8):541
pubmed: 32411764
Oncology. 2013;85(3):153-9
pubmed: 23988857
Cancers (Basel). 2020 Mar 10;12(3):
pubmed: 32164265
PLoS One. 2020 Mar 26;15(3):e0230879
pubmed: 32214401
J Vasc Interv Radiol. 2015 Jun;26(6):816-24.e1
pubmed: 25824315
Cell Mol Biol (Noisy-le-grand). 2017 Aug 30;63(8):30-32
pubmed: 28886327
Oncotarget. 2017 May 23;8(21):34954-34960
pubmed: 28430597
Liver Cancer. 2019 Oct;8(5):387-402
pubmed: 31768347
J Hepatol. 2011 May;54(5):948-55
pubmed: 21145847
Liver Int. 2019 Nov;39(11):2008-2023
pubmed: 31433891
Clin Pract (Lond). 2018;15(Spec Issue):625-634
pubmed: 29951199
Proc Natl Acad Sci U S A. 2012 Aug 7;109(32):E2165-72
pubmed: 22753481
Cancer Med. 2020 Jul;9(14):4962-4970
pubmed: 32419290
Semin Oncol. 2014 Apr;41(2):185-94
pubmed: 24787292
Semin Oncol. 2014 Jun;41(3):415-21
pubmed: 25023358
Cancer Manag Res. 2020 May 14;12:3433-3444
pubmed: 32523374
Eur J Cancer. 2012 Sep;48(13):1977-87
pubmed: 22325840
Medicine (Baltimore). 2020 May 29;99(22):e19958
pubmed: 32481366
Angiogenesis. 2003;6(4):283-7
pubmed: 15166496
Int J Surg. 2019 Dec;72:156-165
pubmed: 31704426
Nat Rev Cancer. 2006 Jan;6(1):24-37
pubmed: 16397525
JAMA Oncol. 2018 Dec 1;4(12):1683-1690
pubmed: 30286235
Cell Physiol Biochem. 2017;44(3):967-981
pubmed: 29179180
Expert Opin Pharmacother. 2015;16(18):2773-80
pubmed: 26479083
J Gastroenterol. 2010 Feb;45(2):146-52
pubmed: 19997856
Br J Cancer. 2012 Sep 4;107(6):988-93
pubmed: 22878374
World J Surg. 2008 Aug;32(8):1757-62
pubmed: 18340479
Am J Surg. 2012 Jan;203(1):101-6
pubmed: 21429472
J Clin Lab Anal. 2019 Nov;33(9):e22999
pubmed: 31418936